Celldex Therapeutics (NASDAQ:CLDX) Upgraded to “Hold” at Zacks Investment Research

Celldex Therapeutics (NASDAQ:CLDXGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. “

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Celldex Therapeutics in a report on Tuesday, March 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Celldex Therapeutics currently has an average rating of “Buy” and a consensus target price of $65.00.

NASDAQ:CLDX opened at $35.53 on Tuesday. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -21.66 and a beta of 2.78. Celldex Therapeutics has a one year low of $21.00 and a one year high of $57.20. The business has a fifty day moving average price of $32.59 and a 200-day moving average price of $38.20.

Celldex Therapeutics (NASDAQ:CLDXGet Rating) last issued its earnings results on Monday, February 28th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.01). The firm had revenue of $0.33 million during the quarter, compared to the consensus estimate of $1.39 million. Celldex Therapeutics had a negative return on equity of 21.98% and a negative net margin of 1,516.04%. During the same period in the prior year, the company posted ($0.26) EPS. Research analysts anticipate that Celldex Therapeutics will post -1.84 earnings per share for the current year.

Large investors have recently modified their holdings of the company. Teacher Retirement System of Texas purchased a new position in shares of Celldex Therapeutics during the third quarter worth approximately $331,000. Geode Capital Management LLC increased its holdings in Celldex Therapeutics by 17.8% during the third quarter. Geode Capital Management LLC now owns 792,507 shares of the biopharmaceutical company’s stock valued at $42,787,000 after buying an additional 119,559 shares during the period. Polar Capital Holdings Plc increased its holdings in Celldex Therapeutics by 44.6% during the third quarter. Polar Capital Holdings Plc now owns 722,843 shares of the biopharmaceutical company’s stock valued at $39,026,000 after buying an additional 222,843 shares during the period. Barclays PLC increased its holdings in Celldex Therapeutics by 82.2% during the third quarter. Barclays PLC now owns 39,768 shares of the biopharmaceutical company’s stock valued at $2,147,000 after buying an additional 17,943 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Celldex Therapeutics during the third quarter valued at approximately $2,395,000. 92.87% of the stock is currently owned by institutional investors and hedge funds.

Celldex Therapeutics Company Profile (Get Rating)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

Featured Articles

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.